315 related articles for article (PubMed ID: 15824861)
1. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation.
Rickels MR; Zhang X; Mumm S; Whyte MP
J Bone Miner Res; 2005 May; 20(5):878-85. PubMed ID: 15824861
[TBL] [Abstract][Full Text] [Related]
2. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
3. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
4. High bone density due to a mutation in LDL-receptor-related protein 5.
Boyden LM; Mao J; Belsky J; Mitzner L; Farhi A; Mitnick MA; Wu D; Insogna K; Lifton RP
N Engl J Med; 2002 May; 346(20):1513-21. PubMed ID: 12015390
[TBL] [Abstract][Full Text] [Related]
5. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
Van Wesenbeeck L; Cleiren E; Gram J; Beals RK; Bénichou O; Scopelliti D; Key L; Renton T; Bartels C; Gong Y; Warman ML; De Vernejoul MC; Bollerslev J; Van Hul W
Am J Hum Genet; 2003 Mar; 72(3):763-71. PubMed ID: 12579474
[TBL] [Abstract][Full Text] [Related]
6. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
7. An autosomal dominant high bone mass phenotype in association with craniosynostosis in an extended family is caused by an LRP5 missense mutation.
Kwee ML; Balemans W; Cleiren E; Gille JJ; Van Der Blij F; Sepers JM; Van Hul W
J Bone Miner Res; 2005 Jul; 20(7):1254-60. PubMed ID: 15940380
[TBL] [Abstract][Full Text] [Related]
8. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling.
Ai M; Holmen SL; Van Hul W; Williams BO; Warman ML
Mol Cell Biol; 2005 Jun; 25(12):4946-55. PubMed ID: 15923613
[TBL] [Abstract][Full Text] [Related]
9. Novel mutation in LRP5 gene cause rare osteosclerosis: cases studies and literature review.
Zhao D; Sun L; Zheng W; Hu J; Zhou B; Wang O; Jiang Y; Xia W; Xing X; Li M
Mol Genet Genomics; 2023 May; 298(3):683-692. PubMed ID: 36971833
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men.
Kiel DP; Ferrari SL; Cupples LA; Karasik D; Manen D; Imamovic A; Herbert AG; Dupuis J
Bone; 2007 Mar; 40(3):587-96. PubMed ID: 17137849
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
12. High bone mass due to novel LRP5 and AMER1 mutations.
Costantini A; Kekäläinen P; Mäkitie RE; Mäkitie O
Eur J Med Genet; 2017 Dec; 60(12):675-679. PubMed ID: 28893644
[TBL] [Abstract][Full Text] [Related]
13. High-bone-mass disease and LRP5.
Whyte MP; Reinus WH; Mumm S
N Engl J Med; 2004 May; 350(20):2096-9; author reply 2096-9. PubMed ID: 15141052
[No Abstract] [Full Text] [Related]
14. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.
Cheung WM; Jin LY; Smith DK; Cheung PT; Kwan EY; Low L; Kung AW
Bone; 2006 Sep; 39(3):470-6. PubMed ID: 16679074
[TBL] [Abstract][Full Text] [Related]
15. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
Bhat BM; Allen KM; Liu W; Graham J; Morales A; Anisowicz A; Lam HS; McCauley C; Coleburn V; Cain M; Fortier E; Bhat RA; Bex FJ; Yaworsky PJ
Gene; 2007 Apr; 391(1-2):103-12. PubMed ID: 17276019
[TBL] [Abstract][Full Text] [Related]
16. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.
Balemans W; Van Hul W
Endocrinology; 2007 Jun; 148(6):2622-9. PubMed ID: 17395706
[TBL] [Abstract][Full Text] [Related]
17. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.
Frost M; Andersen T; Gossiel F; Hansen S; Bollerslev J; van Hul W; Eastell R; Kassem M; Brixen K
J Bone Miner Res; 2011 Aug; 26(8):1721-8. PubMed ID: 21351148
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.
Ai M; Heeger S; Bartels CF; Schelling DK;
Am J Hum Genet; 2005 Nov; 77(5):741-53. PubMed ID: 16252235
[TBL] [Abstract][Full Text] [Related]
19. Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization.
Roetzer KM; Uyanik G; Brehm A; Zwerina J; Zandieh S; Czech T; Roschger P; Misof BM; Klaushofer K
Bone; 2018 Feb; 107():154-160. PubMed ID: 29208525
[TBL] [Abstract][Full Text] [Related]
20. High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6).
Brance ML; Brun LR; Cóccaro NM; Aravena A; Duan S; Mumm S; Whyte MP
Bone; 2020 Dec; 141():115550. PubMed ID: 32730923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
